Mikulski D - Search Results

1

High serum miR-223-3p expression level predicts complete response and prolonged overall survival in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation.

Mikulski D, Nowicki M, Dróźdż I, Misiewicz M, Kościelny KP, Okoński K, Krawiec K, Perdas E, Wierzbowska A, Fendler W. Mikulski D, et al. Front Oncol. 2023 Sep 27;13:1250355. doi: 10.3389/fonc.2023.1250355. eCollection 2023. Front Oncol. 2023. PMID: 37829335 Free PMC article.

2

Quantitative structure-antioxidant activity relationship of trans-resveratrol oligomers, trans-4,4'-dihydroxystilbene dimer, trans-resveratrol-3-O-glucuronide, glucosides: trans-piceid, cis-piceid, trans-astringin and trans-resveratrol-4'-O-beta-D-glucopyranoside.

Mikulski D, Molski M. Mikulski D, et al. Eur J Med Chem. 2010 Jun;45(6):2366-80. doi: 10.1016/j.ejmech.2010.02.016. Epub 2010 Feb 12. Eur J Med Chem. 2010. PMID: 20199826

3

Quantum-chemical study of interactions of trans-resveratrol with guanine-thymine dinucleotide and DNA-nucleobases.

Mikulski D, Szeląg M, Molski M. Mikulski D, et al. J Mol Model. 2011 Dec;17(12):3085-102. doi: 10.1007/s00894-011-0999-2. Epub 2011 Mar 1. J Mol Model. 2011. PMID: 21360171

4

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib.

Robak P, Węgłowska E, Dróżdż I, Mikulski D, Jarych D, Ferlińska M, Wawrzyniak E, Misiewicz M, Smolewski P, Fendler W, Szemraj J, Robak T. Robak P, et al. Among authors: mikulski d. Mediators Inflamm. 2020 Jun 6;2020:1835836. doi: 10.1155/2020/1835836. eCollection 2020. Mediators Inflamm. 2020. PMID: 32587468 Free PMC article.

5

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients.

Robak P, Dróżdż I, Jarych D, Mikulski D, Węgłowska E, Siemieniuk-Ryś M, Misiewicz M, Stawiski K, Fendler W, Szemraj J, Smolewski P, Robak T. Robak P, et al. Among authors: mikulski d. Cancers (Basel). 2020 Sep 9;12(9):2569. doi: 10.3390/cancers12092569. Cancers (Basel). 2020. PMID: 32916955 Free PMC article.

6

The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib.

Robak P, Jarych D, Mikulski D, Dróżdż I, Węgłowska E, Kotkowska A, Misiewicz M, Smolewski P, Stawiski K, Fendler W, Szemraj J, Robak T. Robak P, et al. Among authors: mikulski d. Cancers (Basel). 2021 Feb 25;13(5):951. doi: 10.3390/cancers13050951. Cancers (Basel). 2021. PMID: 33668794 Free PMC article.

7

Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.

Robak P, Szemraj J, Mikulski D, Drozdz I, Juszczak K, Jarych D, Misiewicz M, Kościelny K, Fendler W, Robak T. Robak P, et al. Among authors: mikulski d. J Clin Med. 2021 Oct 28;10(21):5028. doi: 10.3390/jcm10215028. J Clin Med. 2021. PMID: 34768548 Free PMC article.

8

Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib.

Mikulski D, Robak P, Perdas E, Węgłowska E, Łosiewicz A, Dróżdż I, Jarych D, Misiewicz M, Szemraj J, Fendler W, Robak T. Mikulski D, et al. J Clin Med. 2021 Dec 26;11(1):112. doi: 10.3390/jcm11010112. J Clin Med. 2021. PMID: 35011853 Free PMC article.

9

Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study.

Mikulski D, Robak P, Ryżewska W, Stańczak K, Kościelny K, Góra-Tybor J, Robak T. Mikulski D, et al. J Clin Med. 2022 Oct 7;11(19):5908. doi: 10.3390/jcm11195908. J Clin Med. 2022. PMID: 36233774 Free PMC article.

10

Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and autologous stem cell transplantation.

Mikulski D, Kościelny K, Nowicki M, Wawrzyniak E, Kalwas M, Kowalik M, Pryt M, Sęczkowska E, Świątek A, Wierzbowska A, Fendler W. Mikulski D, et al. Leuk Lymphoma. 2023 Jan;64(1):98-106. doi: 10.1080/10428194.2022.2136946. Epub 2022 Nov 1. Leuk Lymphoma. 2023. PMID: 36318865

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

85 results

Search Page

Filters